Caribou Biosciences (CRBU) Total Current Liabilities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Total Current Liabilities data on file, last reported at $19.7 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 30.95% year-over-year to $19.7 million in Q1 2026; TTM through Mar 2026 was $19.7 million, a 30.95% decrease from a year earlier, with the FY2025 full-year figure at $25.4 million, down 17.09% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $19.7 million, down from $25.4 million in the prior quarter.
• Over the last five years, Total Current Liabilities for CRBU reached as high as $34.4 million in Q2 2023 and fell as low as $19.7 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $28.2 million across 5 years, with a median of $28.5 million in 2025.
• Across the five-year window, Total Current Liabilities soared 30.88% in 2024 and slumped 30.95% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $28.1 million in 2022, then gained by 0.62% to $28.3 million in 2023, then advanced by 8.3% to $30.7 million in 2024, then dropped by 17.09% to $25.4 million in 2025, then declined by 22.59% to $19.7 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $19.7 million in Q1 2026, $25.4 million in Q4 2025, and $28.1 million in Q3 2025.